Compounds > 5-benzimidazolecarboxylic acid
Page last updated: 2024-11-08

5-benzimidazolecarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-benzimidazolecarboxylic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID459456
CHEMBL ID1774061
SCHEMBL ID5946
MeSH IDM0444643

Synonyms (63)

Synonym
HMS1757K02
AC-2664
BB 0258867
BB 0256530
OPREA1_327730
1h-benzimidazole-5-carboxylic acid
5-benzimidazolecarboxylic acid
OPREA1_100412
5-benzimidazolecarboxylic acid, 96%
1h-benzimidazole-6-carboxylic acid
STK325324
B1763
5-carboxybenzimidazole
15788-16-6
AKOS000267818
3h-benzimidazole-5-carboxylic acid
benzimidazole-5-carboxylic acid
inchi=1/c8h6n2o2/c11-8(12)5-1-2-6-7(3-5)10-4-9-6/h1-4h,(h,9,10)(h,11,12)
coypldixzodddl-uhfffaoysa-
chembl1774061 ,
bdbm50017194
AKOS000119390
1h-benzoimidazole-5-carboxylic acid
A3471
1h-benzimidazole-5-carboxylicacid
1h-1,3-benzodiazole-5-carboxylic acid
1h-benzimadazole-5-carboxylic acid
1h-benzo[d]imidazole-5-carboxylic acid
3h-benzo[d]imidazole-5-carboxylic acid
F1791-0906
FS-2574
AM20050363
AB01058
1h-benzoimidazole-6-carboxylic acid
CL3437
FT-0620037
AB00443575-03
SCHEMBL5946
SY002468
mfcd00011555
5-benzimidazole-carboxylic acid
1h-benzo[d]imidazole-6-carboxylic acid
5-benzoimidazole carboxylic acid
1h-benzo[d]imidazole-5carboxylic acid
benzimidazol-5-carboxylic acid
3h-benzoimidazole-5-carboxylic acid
5-benzimidazole carboxylic acid
1h-benzimidazole-5-carboxylic acid #
W-201426
1h-1,3-benzodiazole-6-carboxylic acid
DS-0595
STR02626
DTXSID70332648
CS-W002064
1h-benzimidazole-6-carboxylic acid, aldrichcpr
Z56922116
1-h-benzimidazole-5-carboxylic acid
NCGC00337578-01
EN300-17352
mfcd03225617
3h-benzo[d]imidazole-5-carboxylicacid
1h-benzo[d]imidazole-5-carboxylicacid
HY-W002064
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
response to hypoxiaDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
protoporphyrinogen IX biosynthetic processDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
heme biosynthetic processDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
heme A biosynthetic processDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
heme B biosynthetic processDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to oxidative stressDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to xenobiotic stimulusDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to herbicideDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to iron ionDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to zinc ionDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to aluminum ionDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to ionizing radiationDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to vitamin B1Delta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to selenium ionDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to activityDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to cobalt ionDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to lipopolysaccharideDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to vitamin EDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to amino acidDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to ethanolDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to arsenic-containing substanceDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to cadmium ionDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to mercury ionDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
heme O biosynthetic processDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
protein homooligomerizationDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to glucocorticoidDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to methylmercuryDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to platinum ionDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
response to fatty acidDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
cellular response to lead ionDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
cellular response to interleukin-4Delta-aminolevulinic acid dehydrataseHomo sapiens (human)
negative regulation of proteasomal protein catabolic processDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
catalytic activityDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
porphobilinogen synthase activityDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
zinc ion bindingDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
identical protein bindingDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
proteasome core complex bindingDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
nucleusDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
cytosolDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
secretory granule lumenDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
extracellular exosomeDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
ficolin-1-rich granule lumenDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
cytosolDelta-aminolevulinic acid dehydrataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1151556Inhibition of Yersinia enterocolitica recombinant PBGS expressed in Escherichia coli using 5-ALA as substrate at 533 uM2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID1151551Inhibition of Vibrio cholerae recombinant PBGS expressed in Escherichia coli using 5-ALA as substrate at 533 uM2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID1151531Inhibition of Pisum sativum PBGS using 5-ALA as substrate2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID1151561Inhibition of Drosophila melanogaster recombinant PBGS using 5-ALA as substrate2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID595491Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 100 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID1151560Inhibition of Toxoplasma gondii recombinant PBGS using 5-ALA as substrate at 533 uM2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID667489Inhibition of recombinant type N-terminal His6-tagged 2 R67 DHFR expressed in Escherichia coli BL21 using DHF as substrate by spectrophotometry2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
AID1151554Stimulation of Vibrio cholerae recombinant PBGS expressed in Escherichia coli using 5-ALA as substrate at 533 uM2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID1151562Inhibition of human PBGS using 5-ALA as substrate2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID1151558Inhibition of Pseudomonas aeruginosa PAO1 recombinant PBGS using 5-ALA as substrate at 533 uM2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID1151557Stimulation of Pseudomonas aeruginosa PAO1 recombinant PBGS using 5-ALA as substrate at 533 uM2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID667492Inhibition of human chromosomal DHFR expressed in Escherichia coli BL21 using DHF as substrate assessed as remaining activity at 10 mM by spectrophotometry relative to control2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
AID1151552Stimulation of Escherichia coli recombinant PBGS using 5-ALA as substrate at 533 uM2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID1151532Inhibition of C-terminal His-tagged Wolbachia PBGS using 5-ALA as substrate2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID1151553Inhibition of Escherichia coli recombinant PBGS using 5-ALA as substrate at 533 uM2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID595490Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 100 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID1151559Stimulation of Toxoplasma gondii recombinant PBGS using 5-ALA as substrate at 533 uM2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID595488Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 100 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595489Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 100 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID1151555Stimulation of Yersinia enterocolitica recombinant PBGS expressed in Escherichia coli using 5-ALA as substrate at 533 uM2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.31 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		2.0610amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
5-aminovaleric acid
5-aminovaleric acid: from red fox anal secretion; RN given refers to parent cpd. 5-aminopentanoic acid : A delta-amino acid comprising pentanoic acid with an amino substituent at C-5; a methylene homologue of gamma-aminobutyric acid (GABA) that is a weak GABA agonist.		2.0610amino acid zwitterion;
delta-amino acid;
omega-amino fatty acid		human metabolite
beta-alanine
[no description available]		2.0610amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter
aminocaproic acid
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.		2.0610amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
glycine
[no description available]		2.0610alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		2.0710aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
benzimidazole
1H-benzimidazole : The 1H-tautomer of benzimidazole.		2.0710benzimidazole;
polycyclic heteroarene
piperonylic acid
piperonylic acid: RN given refers to parent cpd; structure. piperonylic acid : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a carboxy group at position 5. It is a natural product isolated from several plant species. It is a selective mechanism-based inactivator of the trans-cinnamate 4-hydroxylase enzyme and exhibits antifungal and skin wound healing properties.		2.0710aromatic carboxylic acid;
benzodioxoles;
monocarboxylic acid		antifungal agent;
EC 1.14.14.91 ( trans-cinnamate 4-monooxygenase) inhibitor;
plant metabolite;
vulnerary
1-hydroxyphthalazine
1-hydroxyphthalazine: RN given refers to cpd with unspecified locants; do not confuse with cpd phthalazinol RN: 56611-65-5		2.0710phthalazines
congo red
Congo Red: An acid dye used in testing for hydrochloric acid in gastric contents. It is also used histologically to test for AMYLOIDOSIS.. Congo Red : An indicator dye that is blue-violet at pH 3.0 and red at pH 5.0.		2.0710bis(azo) compound
omega-aminoenantic acid
[no description available]		2.0610medium-chain fatty acid
5-imidazolepropionic acid
5-imidazolepropionic acid: competitive inhibitor of urocanase reaction which catalyzes conversion of urocanate into imidazolone propionate; structure. dihydrourocanic acid : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 3 has been replaced by an imidazol-4-yl group.		2.0610imidazoles;
monocarboxylic acid
1h-benzotriazole-5-carboxylic acid
1H-benzotriazole-5-carboxylic acid: structure given in first source		2.0710
imidazoleacetic acid
imidazoleacetic acid: RN given refers to cpd without specific location of acetic acid attachment identified; structure. imidazol-5-ylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by an imidazol-5-yl group.. imidazol-4-ylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by an imidazol-4-yl group.		2.0610imidazoles;
monocarboxylic acid		metabolite;
mouse metabolite
6-Methoxy-2-naphthoic acid
[no description available]		2.0710naphthoic acid
imidazol-1-ylacetic acid
imidazol-1-ylacetic acid : An imidazolyl carboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by an imidazol-1-yl group.		2.0610imidazolyl carboxylic acidmetabolite
urocanic acid
Urocanic Acid: 4-Imidazoleacrylic acid.. urocanic acid : An alpha,beta-unsaturated monocarboxylic acid that is prop-2-enoic acid substituted by a 1H-imidazol-4-yl group at position 3. It is a metabolite of hidtidine.. trans-urocanic acid : A urocanic acid in which the double bond of the carboxyethene moiety has E configuration.		2.0610urocanic acidhuman metabolite
1-propan-2-yl-5-benzotriazolecarboxylic acid
[no description available]		2.0710benzotriazoles
3-(1H-imidazol-1-yl)propanoic acid
[no description available]		2.0610imidazolyl carboxylic acidhuman urinary metabolite
snap 5114
[no description available]		2.0610
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		2.0710carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Porphyria
[description not available]		02.110
Porphyrias
A diverse group of metabolic diseases characterized by errors in the biosynthetic pathway of HEME in the LIVER, the BONE MARROW, or both. They are classified by the deficiency of specific enzymes, the tissue site of enzyme defect, or the clinical features that include neurological (acute) or cutaneous (skin lesions). Porphyrias can be hereditary or acquired as a result of toxicity to the hepatic or erythropoietic marrow tissues.		02.110